Clinical Trial Search

Primary: Difference Between AMR101 (Ethyl Icosapentate) and Placebo Treatment Groups in Triglyceride Lowering Effect — -7.0; -26.6; 9.7 Percent change from baseline — p=<0.0001

Primary: Fasting Serum Triglycerides — 705; 1827; 1511; 1007 mg/dL

Primary: Pre- and Post-Intervention Triglyceride Levels — 231; 209; 201; 140 mg/dL

Primary: Difference Between AMR101 (Ethyl Icosapentate) and Placebo Treatment Groups in Triglyceride Lowering Effect — -5.6; -17.5; 5.9 Percent change from baseline — p=<0.0001

Primary: Percent Change From Baseline to End of Study (EOS) in Fasting Serum Triglycerides (TG) — -47.32; -32.95; -27.30 Percent Change — p=0.0063

Primary: Change (Reduction) in Triglycerides Levels From Baseline to End of Treatment (Week 8) — 67.95; 78.61; 22.31 mg/dL

Primary: Percent Change of Fasting Triglyceride(TG) Levels From Baseline to Week 12 — -56.00; -7.97 Percent of Change — p=<0.0001

Primary: Percentage Change in Serum Triglyceride Levels From Baseline to Week 12 of Study Treatment — -39.1; -14.6 Percent change (%) — p=<0.01

Primary: Difference Between Treatments in Liquid Meal Tolerance Test (LMTT) Matsuda Insulin Sensitivity Index (MISI). — 3.2; 3.3 Index value — p=0.959

Primary: HDL 15-HEPE — 3.7; 10.4 nmol/mmol phospholipid

Primary: Percent Change From Baseline to Week 12 in Calculated Low-Density Lipoprotein-Cholesterol (LDL-C) — -17.9; -25.0; -26.6; -2.1 Percent Change — p=<0.0001

Primary: Percent Change in Fasting TG From Baseline to Week 12 — -58.89; -22.94 Percent change — p=<0.0001

Primary: Absolute Change From Baseline to Month 3 in Fasting Triglycerides (TG) — -550.00 mg/dL

Primary: Changes Serum Triglyceride Levels — 223.1; 241.2; 227.0; 267.2 mg/dl — p=0.0001

Primary: Mean ApoB Concentration Before and After Evolocumab — 75.9; 35.3 mg/dL — p=<0.001

Primary: Percent Change in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Week 8 During 10 mg Atorvastatin Treatment Period — -40.2; -33.7 percent change…

Primary: Percent Change From Baseline in Fasting Triglycerides (TG) at the Primary Analysis Time Point — 6; -23; -56; -60 percent change — p=0.0042

Primary: Change in Triglyceride Level — -52; -16 mg/dL

Primary: Percent Change in Fasting Triglycerides From Baseline to 12 Weeks — 45.6; 3.7; -13.9 percent change — p=0.0538

Primary: Proportion of Subjects With Triglycerides <200 mg/dL — 12 participants

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 106; 110; 109 participants

Primary: Percent Change From Baseline in Fasting Triglycerides (TG) Level Following 12 Weeks of Repeated IV Doses of Evinacumab in Actual Cohort 3 Participants — 19.2; -37.2…

Primary: Percent Change From Baseline to Week 8 in Serum Triglyceride (TG) — -57.33; -11.85 percent change from Baseline — p=<0.001

Primary: Change in Triglyceride Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group. — -34; 40 mg/dl — p=0.01

Primary: Percent Change From Baseline in Fasting TG at Month 6 — -7.77; -57.05; -60.92 Percent Change — p=<0.0001

Primary: Triglyceride Levels — 135.5; 108.3; 152.7; 109 milligram/deciliter

Primary: Percent Change From Baseline in Fasting Triglycerides Levels at End of the Treatment (Week 27) — -59.9 percent change

Primary: Percent Change From Baseline in Triglyceride Level at the Final Visit — -10.93; -22.65; -11.30 percent change — p=0.8760

Primary: Changes in Systolic Blood Pressure During Initial Intralipid Infusion — 23; 13 mmHg

Primary: Change in Triglycerides From Baseline to 16 Weeks — -54.13 mg/dL